Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.
Updated: Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome
Danish drugmaker Lundbeck will buy La Jolla, CA-based Longboard Pharmaceuticals for $2.6 billion in cash, the companies said Monday morning, marking … Sign up to